HANNAH DARCY: Open Payments
NPI 1417676842 · MUSKEGON, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$872 in 48 payments from 19 companies in 2025. Trend: 2023 $189 · 2024 $790 · 2025 $872
Food & beverage: $872
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 11 | $163 |
| Otsuka America Pharmaceutical, Inc. | 5 | $103 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $97 |
| Teva Pharmaceuticals USA, Inc. | 4 | $82 |
| Neurocrine BioSciences, Inc. | 3 | $56 |
| Novo Nordisk Inc | 3 | $48 |
| ABBVIE INC. | 2 | $45 |
| ABIOMED | 2 | $35 |
| Lilly USA, LLC | 2 | $35 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $33 |
Products named: TRELEGY ELLIPTA, REXULTI, CAPLYTA, AUSTEDO XR, INGREZZA, MOUNJARO, XIFAXAN, Saxenda.
Industry payments across MI — which companies pay providers there.
